[Clinical and laboratory presentation of the influenza A (H1N1pdm 2009) in children and adults during the period of 2009-2013 in St. Petersburg].

Comparative analysis of the clinical laboratory data from 419 children and 468 adults hospitalized during the pandemic of A (H1N1pdm 2009) and pre- and post-pandemic periods (2010-2013) showed that the clinical presentation of the pandemic influenza in patients of all ages is generally typical for influenza, and its character is determined by the degree of involvement of lungs in the process. Besides, the incidence of pneumonia in adults is statistically significantly higher than in children. During all compared periods hyperthermia (≥ 39 degrees C), hemorrhagic and dyspeptic syndrome were observed. Some differences in the main clinical manifestations of pneumonia in recovered patients and patients who died of the severe pandemic influenza were observed. The regularities of the cytokine reactions depending on the intensity of intoxication and occurrence of complications were determined in patients of all ages. Medical efficacy of inclusion of antiviral chemotherapeutic agents into complex influenza treatment was proved.

[Hospital respiratory infections in children]. / Gospitalnye respiratornye infektsii u detei.

Acute respiratory superinfections (ARS) induced by secondary nosocomial respiratory pathogens and characterized by the subsequent generalization of the process have been reported as one of the main contributions to pediatric inpatient mortality. The recurrent infections were observed in all types of hospitals; they might be induced by the whole group of respiratory pathogens, but adeno-, coronaviral and pneumococcal ones are predominating. The ARS clinical picture showed various patterns determined both by the etiology of basic and recurrent infection and by a child's immunity. There was a correlation between the severity of ARS and the level of specific immunoglobulins, especially of secretory origin.

[Remantadine in the treatment of influenza in children]. / Primenenie remantadina dlia lecheniia grippa u detei.

The therapeutical efficacy of remantadine was studied in influenza in- and out-patients aged 3-14 years during consecutive influenza epidemics. The drug was given to ill children on the first or second day from the onset of the disease at a dose of 1.5 mg/kg of body weight 3 times a day for 3 days. The curative effect of remantadine was established not only in influenza A, but also in influenza B infections, as well as in mixed infections with other respiratory agents and with pathogens of non-influenza etiology, which might be the result of its antitoxic activity. Remantadine application decreased fever and complication rates and reduced the duration of intoxication symptoms and the diseases as a whole. A more pronounced drug activity was observed when given to children on the first day of the diseases. Remantadine exerted no toxic effect on the basic functions of the child's body. Ill children displayed no inhibitory activity on cell and humoral immunity, as well as on a serum antibody response to hemagglutinin of influenza virus.